Detalhe da pesquisa
1.
Assessment of anti-SARS-CoV-2 antibodies level in convalescents plasma.
J Med Virol
; 94(3): 1130-1137, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34738646
2.
Combined therapy with CD4+ CD25highCD127- T regulatory cells and anti-CD20 antibody in recent-onset type 1 diabetes is superior to monotherapy: Randomized phase I/II trial.
Diabetes Obes Metab
; 24(8): 1534-1543, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35441440
3.
Factors affecting long-term efficacy of T regulatory cell-based therapy in type 1 diabetes.
J Transl Med
; 14(1): 332, 2016 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27903296
4.
PD-1 Receptor (+) T cells are associated with the efficacy of the combined treatment with regulatory t cells and rituximab in type 1 diabetes children via regulatory t cells suppressive activity amelioration.
Int Immunopharmacol
; 132: 111919, 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38554443
5.
Correlation of ENT Symptoms with Age, Sex, and Anti-SARS-CoV-2 Antibody Titer in Plasma.
J Clin Med
; 12(2)2023 Jan 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36675539
6.
Administration of CD4+CD25highCD127-FoxP3+ Regulatory T Cells for Relapsing-Remitting Multiple Sclerosis: A Phase 1 Study.
BioDrugs
; 35(1): 47-60, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33400237
7.
Proinsulin-specific T regulatory cells may control immune responses in type 1 diabetes: implications for adoptive therapy.
BMJ Open Diabetes Res Care
; 8(1)2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32098895